Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 4:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,772 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Illness Clear all
Recruiting Not applicable Interventional

Mind Body Intervention for Long COVID-19

NCT06045338
View directory record Official record
Conditions
Long COVID, Post-Acute Sequelae of COVID-19, COVID Long-Haul
Interventions
Mind Body Intervention #1
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jun 10, 2026, 4:43 PM EDT
Withdrawn Early Phase 1 Interventional

Intraductal Liposomal Bupivacaine for Chronic Pancreatitis

NCT04611958
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
ERCP with Bupivacaine infusion
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Phase 1 Interventional

A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

NCT01290549
View directory record Official record
Conditions
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Interventions
Polatuzumab Vedotin, Rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
7
States / cities
Stanford, California • Sarasota, Florida • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis

NCT00548249
View directory record Official record
Conditions
End-Stage Renal Disease (ESRD)
Interventions
Standard Bicarbonate Solution, Soluble Ferric Pyrophosphate
Device · Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
27
States / cities
Tempe, Arizona • Hacienda Heights, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

NCT00021749
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, CLL
Interventions
Oblimerson sodium, G3139
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
3
States / cities
New Hyde Park, New York • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2009 · Synced Jun 10, 2026, 4:43 PM EDT
Recruiting No phase listed Observational

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

NCT07264426
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jun 10, 2026, 4:43 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers

NCT04722835
View directory record Official record
Conditions
Copd, Smoking, Tobacco Use
Interventions
Bronchoscopy with Bronchoalveolar Lavage (BAL)
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Phase 1 Interventional

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

NCT00104923
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
fenretinide
Drug
Lead sponsor
California Cancer Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin

NCT01238796
View directory record Official record
Conditions
Kidney Diseases, End Stage Renal Disease
Interventions
telavancin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Early Phase 1 Interventional

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

NCT00424242
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Pemetrexed
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Jun 10, 2026, 4:43 PM EDT
Withdrawn Phase 2 Interventional

A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

NCT00594555
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Blast Crisis, Acute Myeloid Leukemia
Interventions
Imatinib Mesylate, CLAG
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2008 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

Coenzyme Q10 Phase III Trial in Gulf War Illness

NCT02865460
View directory record Official record
Conditions
Gulf War Illness, Chronic Fatigue, Ubiquinol, Coenzyme Q10
Interventions
Ubiquinol, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Not applicable Interventional

Observational Study of the Wellinks Solution Impact on Quality of Life and Clinical Outcomes in Patients With COPD

NCT05259280
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease Severe, Chronic Obstructive Pulmonary Disease Moderate
Interventions
Wellinks
Other
Lead sponsor
Convexity Scientific Inc
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Not applicable Interventional Results available

Treating Chronic Pain in Gulf War Illness

NCT02378025
View directory record Official record
Conditions
Chronic Pain, Gulf War Illness, Chronic Illness
Interventions
Yoga Group, Pain Management Wellness Group
Behavioral
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
42 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Jun 10, 2026, 4:43 PM EDT
Withdrawn Phase 4 Interventional

Placebo Controlled Evaluation of Sedation and Physiological Response to Intranasal Dexmedetomidine in Severe COPD

NCT02773797
View directory record Official record
Conditions
COPD
Interventions
IN-DEX 1.0 mcg/kg, intranasal saline, IN-DEX 1.5 mcg/kg, intranasal saline, Placebo - Saline
Drug
Lead sponsor
Dayton VA Medical Center
Federal
Eligibility
45 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Jun 10, 2026, 4:43 PM EDT
Not listed Phase 2Phase 3 Interventional

New Needle for Two-Needle Hemodialysis

NCT01416896
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Hemodialysis using the standard venous needle, Hemodialysis using a new venous needle, the "BME needle"
Procedure
Lead sponsor
Biomedical Enterprises Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2011 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Not applicable Interventional

Problem-Solving Therapy for People With Major Depression and Chronic Obstructive Pulmonary Disease

NCT00601055
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Depression
Interventions
Problem Solving-Rx Adherence (PSA), PID-C
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years to 95 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

NCT02481297
View directory record Official record
Conditions
Leukemia, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia
Interventions
Lirilumab, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Jun 10, 2026, 4:43 PM EDT
Recruiting Phase 2 Interventional

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

NCT06967610
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia (SLL)
Interventions
Pirtobrutinib, Venetoclax, Obinutuzumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jun 10, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease

NCT02157935
View directory record Official record
Conditions
COPD Patients
Interventions
Symbicort, Formoterol turbohaler, Placebo for Symbicort pMDI, Placebo for Formoterol Turbohaler
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 95 Years
Enrollment
2,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
224
States / cities
Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Jun 10, 2026, 4:43 PM EDT
Withdrawn Not applicable Interventional

Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease

NCT01426724
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
Contrast Enhanced Ultrasonography
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Jun 10, 2026, 4:43 PM EDT
Completed No phase listed Observational

Long-term Study on Anti-HBV Effect of Tenofovir and Resistance Surveillance in Asian-American Adult Patients

NCT01267162
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Not listed
Lead sponsor
Medical Procare PLLC
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Los Angeles, California • San Jose, California • Flushing, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Jun 10, 2026, 4:43 PM EDT
Completed No phase listed Observational

Epigenetics and Psychoneurologic Symptoms in Women With Breast Cancer

NCT01411943
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 81 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Newport News, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Jun 10, 2026, 4:43 PM EDT
Completed No phase listed Observational

A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)

NCT06744374
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BGF, MITT
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
22,369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jun 10, 2026, 4:43 PM EDT